Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 05 April, 2013 and appeared in  MedicationAging & DiabetesOncologyInsulinIssue 671

Metformin May Delay Aging and Cancer Progression

Metformin delays aging and cancer progression by reducing the production of....
Advertisement

A research team from the University of Montreal revealed the mechanism of how metformin slows aging and cancer progression. In a study, they found that metformin reduces the production of inflammatory cytokines. These inflammatory cytokines are key players activating the immune system in tissue damage during aging and tumor growth in cancer development.

Dr. Gerardo Ferbeyre and colleagues found that metformin decreases cytokines by disrupting a protein called NF-kB that would normally trigger cytokine activation and the immune system. When cytokines are overproduced, this leads to pathological inflammation that is involved in both the aging and cancer processes.

Dr. Ferbeyre said, "This is an important finding with implications for our understanding on how the normal organism defends itself from the threat of cancer and how a very common and safe drug may aid in treatment of some cancers and perhaps slow down the aging process." He added, "It remains that determining the specific targets of metformin would give us an even better opportunity of profit from its beneficial effects. That's what we want to figure out next." This finding may be an important step in finding a place for metformin therapy in anti-cancer and anti-aging therapy.

"Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-B activation" Aging Cell, March 2013 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 April, 2013 and appeared in  MedicationAging & DiabetesOncologyInsulinIssue 671

Past five issues: Diabetes Clinical Mastery Series Issue 198 | Issue 738 | Diabetes Clinical Mastery Series Issue 197 | Issue 737 | Diabetes Clinical Mastery Series Issue 196 |

2014 Most Popular Articles:

U.S. FDA Approves Inhaled Insulin: What Medical Professionals Need to Know
Posted July 04, 2014
Newly Updated: Comprehensive List of Insulins
Posted June 30, 2014
ADA: Lantus Losing Its Superiority to Newer Treatments
Posted June 20, 2014
Can Insulin Treatment Do More Harm Than Good for Older Type 2's?
Posted July 04, 2014
ADA: Another Inhaled Insulin Treatment for Type 1 and 2 Diabetes May Be Coming Soon
Posted June 26, 2014
Too Much Medication for Elderly Diabetes Patients?
Posted July 11, 2014
ADA: New HbA1c Target of 7.5% for Type 1 Children and Older Adults
Posted June 20, 2014
ADA: The Bionic Pancreas
Posted June 26, 2014
Which Is Better for BG Control: Aerobic or Anaerobic Exercise?
Posted July 11, 2014
Effects of Diabetes and Obesity on Normal Flora
Posted July 04, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
Cast Your Vote
Do you offer group education sessions in your practice?
CME/CE of the Week
Jeffrey Mechanick

Category: General Diabetes
Credits: .75
Search Articles On Diabetes In Control